Nick Lynch, consultant at The Pistoia Alliance discusses how technology, including artificial intelligence (AI), can help automate the lab and accelerate outcomes.
As part of our feature on serialisation, Joseph L Lipari, director, Cloud Implementation Services, Systech International, reveals the importance of blockchain in closing the supply chain trust gap.
According to Frank Austin Nothaft, GTM lead for Genomics, Databricks, a unified approach to big data is the best way to get the most value. Here, he tells us more.
Here, Dr Natasha Varvogli, intellectual property consultant, and Maria Andrielou, marketing & communication at VIO Chemicals, look at patents and their role in the pharma industry.
Michael Avraam, global product manager at ChargePoint Technology discusses the evolution of containment strategies, specifically within the role of containment verification and monitoring technology.
Machine learning offers considerable potential for streamlining and transforming routine information processes in life sciences — but could more creative applications of artificial intelligence take things further still? AMPLEXOR’s Siniša Belina asse
Dr Andrew Rut, CEO of SaaS provider My Meds & Me discusses why AI can revolutionise drug development and healthcare but caution over data is critical for success.
GlobalData, a data and analytics company, has reported that further development of chimeric antigen receptor (CAR)-T cell therapies in solid tumours will require collaboration with industry.
In this exclusive interview, we discuss the digitalisation of the supply chain, compliance with European Falsified Medicines Directive and TraceLink’s Product Information Manager with the company’s vice president, solutions marketing, Dan Walles.
Data and analytics company, GlobalData, has revealed that it believes new launches into the epinephrine injection device market will have the potential to completely transform the space.
In preparations for Brexit, the EMA has redistributed the UK’s product portfolio to other EU members and is not allocating any centralised marketing authorisation applications to the MHRA. We take a closer look…
